Background. Lyme encephalopathy, characterized by nonspecific neurobehavioral symptoms including mild cognitive difficulties, may occur in patients with systemic Lyme disease and is often mistakenly attributed to central nervous system (CNS) infection. Identical symptoms occur in many inflammatory states, possibly reflecting the effect of systemic immune mediators on the CNS.
Lyme neuroborreliosis (LNB) occurs in 10%-15% of individuals infected with the tick-borne spirochetes Borrelia burgdorferi sensu stricto, Borrelia afzelii, and Borrelia garinii [1] . Remarkably, despite B. burgdorferi central nervous system (CNS) invasion-typically with symptomatic Lyme meningitis-spirochetes can be isolated from CSF in only about 10%-15% of patients with demonstrated CSF inflammation [2] , presumably because few organisms are present in accessible fluids. In addition, just as in myriad other systemic inflammatory disorders, patients with non-CNS Lyme disease can experience impactful neurobehavioral difficulties, with "objectively demonstrable cognitive abnormalities on mental status testing, " termed Lyme encephalopathy [3] . The mechanisms by which a small number of organisms cause significant inflammatory CNS disease, or by which non-CNS infection alters behavior, remain unclear. However, understanding these phenomena in Lyme disease might provide insights generalizable to other infectious and inflammatory disorders.
Because there is no evidence that B. burgdorferi produces exotoxins, the most likely mechanism by which infection might cause amplified or distant actions involves immune stimulation and soluble neuroimmunomodulators [4] [5] [6] . Studies have emphasized elevated CXCL13 in CSF [7, 8] , with associated B-cell infiltration [9] early in CNS infection. T-helper (Th) 17-type inflammatory responses are detectable later in CNS infection [10] and have been proposed to play roles in Lyme arthritis [11, 12] and in posttreatment neurobehavioral symptoms [13] . We therefore measured cytokines and chemokines in CSF and serum accumulated over several decades of evaluating patients with suspected LNB, to explore possible immune dysregulation in active neuroborreliosis and in Lyme encephalopathy.
anonymous adults undergoing myelography. Normal donor serum samples were obtained from Bioreclamation IVT, with informed consent under an independent institutional review board-approved protocol. Donors with known active infections and antibiotic or steroid use within the previous month were excluded. Serum samples were tested by the supplier in accordance with Food and Drug Administration regulations and found to be negative for human immunodeficiency virus (HIV) type 1 and type 2 and hepatitis C virus antibodies, and nonreactive for hepatitis B surface antigen, HIV-1 RNA, and hepatitis C virus RNA. Serologic testing for Lyme disease was performed as described below. Patient characteristics are summarized in Tables 1 and 2 and Supplementary Table S1 .
Enzyme-Linked Immunosorbent Assay and Western Blot Analysis to Detect B. burgdorferi Antibodies
After collection, serum and CSF samples from symptomatic patients were assayed for B. burgdorferi-specific immunoglobulin (Ig) G, IgA, and IgM using an enzyme-linked immunosorbent assay (ELISA) against B. burgdorferi whole-cell sonicate [14] . Serum ELISA results were expressed as the serum index, equal to (patient optical density [OD])/(normal control mean OD + 3 standard deviations); patients were considered seropositive if this index was ≥1. As previously demonstrated with this method, values of the CSF/serum index, (ratio of CSF OD to serum OD, after normalizing for IgG concentration) ≥0.9 indicated intrathecal synthesis of B. burgdorferi-specific antibodies (ITAb), confirming the diagnosis of LNB in symptomatic patients with CSF pleocytosis [15] . At the time of cytokine analysis, serum samples were analyzed using C6 Lyme ELISA (Immunetics). In patients with borderline or positive ELISA results, Western blot analysis was performed, using MarDx IgM and IgG Marblots (Trinity Biotech).
Multiplex Assays
Cytokines were measured using ProcartaPlex Luminex xMAP custom multiplex immunoassays (Affymetrix-eBioscience), read on a Luminex MAGPIX instrument. The manufacturer's protocol was modified to include an expanded 14-point standard curve to improve accuracy at lower concentrations. Analytes (listed in Supplementary Tables S2 and S3) were chosen based on results from published studies [4, 10, 13] and our pilot studies, using more comprehensive cytokine multiplex panels.
Data Analysis
For analysis and graphing, samples with concentrations greater than the highest point on the standard curve were assigned the value of the highest standard; those below the lowest standard a value half the lowest standard. Kruskal-Wallis test and Dunn multiple-comparison posttests were performed in GraphPad Prism version 6. Principal component (PC) analysis was performed with Minitab statistical software version 17. Because many cytokines are coordinately up-regulated in response to infection or inflammation, Bonferroni correction was not applied.
RESULTS

CSF Cytokines and Chemokines in Neuroinflammation (Lyme, Non-Lyme) Versus Lyme Encephalopathy
To determine whether CXCL13 or other CSF cytokines or chemokines could be useful in the diagnosis of early LNB, we performed multiplex immunoassays on samples from 74 patients who underwent lumbar puncture for possible LNB. Patients were divided into 5 groups (Supplementary Table S1 ). Patients with definite active LNB had B. burgdorferi-specific intrathecal antibody (ITAb) production, CSF pleocytosis >5 cells/µl, and typical symptoms. Patients with "possible early LNB" also had symptoms strongly suggestive of neuroborreliosis, including symptomatic meningitis in 1, cranial neuritis in 6, and radiculitis in 2. All were seropositive for B. burgdorferi and had CSF pleocytosis but lacked ITAb, precluding a definite LNB diagnosis. We compared definite and possible early LNB groups to patients with Lyme encephalopathy (with mild objective cognitive impairment and seropositivity for Lyme disease but normal CSF findings), controls with non-Lyme neuroinflammation (non-Lyme NI), and controls with nonneuroinflammatory disorders. Controls with non-Lyme NI from our biobank had CSF pleocytosis and negative Lyme ELISA results but had been evaluated for possible LNB, making them a clinically relevant comparison group for determining the specificity of putative biomarkers of early LNB.
Numerous inflammatory markers were elevated in patients with definite LNB, possible early LNB, and non-Lyme NI-all of whom had CSF pleocytosis. Levels of CXCL13, CXCL12, CXCL10, CXCL8, CXCL1, eotaxin, interleukin 12, interferon γ, interleukin 1α, interleukin 6, tumor necrosis factor α, interleukin 10, interleukin 1 receptor antagonist, and granulocyte-macrophage colony-stimulating factor were elevated in patients with definite LNB, compared with controls with nonneuroinflammatory disorders (Supplementary Table S2 ). Many of these cytokines were also significantly elevated in patients with possible early LNB and non-Lyme NI, but none distinguished these groups from each other. Patients with Lyme encephalopathy did not have elevations in any of the CSF inflammatory markers analyzed, clearly distinguishing them from patients with LNB.
CSF CXCL13 in LNB With ITAb Production
Previous reports suggested that CSF CXCL13 may be a useful diagnostic marker for definite CNS LNB (ie, including B. burgdorferi-specific ITAbs) [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] ; in our initial study, CSF CXCL13 was the most highly elevated chemokine in such patients. The utility of this marker is less clear in patients with strongly suspected LNB, with positive Lyme serology but a negative CSF antibody index. Therefore, we analyzed CXCL13 in 191 patients with a range of neuroinflammatory (n = 63; Table 1 ) and nonneuroinflammatory (n = 128; Table 2 ) disorders, including additional patients with neurobehavioral symptoms ranging from encephalopathy to headaches, with or without a history of Lyme disease.
As in our preliminary study, CSF CXCL13 levels were strikingly elevated in all patients with definite LNB ( Figure 1A ). Although CXCL13 was moderately correlated with CSF white blood cell count ( Figure 1B ), pleocytosis alone did not explain the dramatic elevations in these patients, with levels of the chemokine in definite LNB far exceeding those in patients with non-Lyme NI with similar pleocytosis. Receiver operating characteristic analysis of the data confirmed earlier reports and showed CSF CXCL13 to be a sensitive and specific marker for definite LNB ( Figure 1C ). However, levels of the chemokine in patients with possible LNB (without detectable ITAb) overlapped with and did not differ significantly from those in patients affected by multiple sclerosis, neurosyphilis, and other CNS infections and neuroinflammatory conditions, including cryptococcal meningitis, viral meningitis, lupus, and multisystem atrophy. Consistent with an earlier report [25] , serum levels of the chemokine were significantly higher in definite LNB than in normal controls (Supplementary Table S3 ). However, the high degree of variability in healthy individuals and in non-LNB controls makes it unlikely that serum CXCL13 would be a useful diagnostic marker.
Serum T-Cell Growth Factor, IL-7, and Neurobehavioral Symptoms
CSF CXCL13 was undetectable in 96% of patients with nonneuroinflammatory disorders, including 94% of patients (79 of 84) with encephalopathy and/or headaches associated with non-CNS Lyme disease ( Figure 1A ), confirming other evidence that their symptoms were not a result of CNS infection or inflammation. To investigate whether systemic inflammation was associated with these neurobehavioral symptoms, and to determine whether Age, mean (SE), y 37 (9) 49 (6) 37 (2) 38 (4) 42 (7) Female sex, No. (%) 4 (50) 6 (55) 24 (80) 1 (33) 4 (36) Symptoms of disease, No. (%)
History of EM 1 (13) 2 (18) 6 (20) (14) 24 (14) 7 (2) 10 (9) 86 ( No. of antibiotic courses, mean (range)
Time since 1st antibiotic treatment, mean (range), mo
Abbreviations: CSF, cerebrospinal fluid; ELISA, enzyme-linked immunosorbent assay; IgG, immunoglobulin G; EM, erythema migrans LNB, Lyme neuroborreliosis; NA, not applicable; SE, standard error; WB, Western blot; WBC, white blood cell; WCS, whole-cell sonicate. a Other non-Lyme neuroinflammatory disorders in patients evaluated for suspicion of LNB included viral meningitis (n = 4) and cryptococcal meningitis, viral encephalitis, vasculitis, neuropathy, plexopathy, lupus, and multisystem atrophy (each n = 1). b Symptom duration was unknown for 9 of 63 patients; "0" represents acute symptoms for <1 month.
c Paired serum samples were available for C6/WB and cytokine analysis for 4 patients with definite LNB and 9 with possible early LNB.
d One patient with LNB received inadequate antibiotic treatment 7 months earlier.
it was specific to Lyme disease, we performed multiplex cytokine analysis on serum samples from both patients with and patients without Lyme disease with similar neurobehavioral symptoms. Compared with normal controls, patients with headaches or encephalopathy showed highly significant elevations in serum levels of interleukin 7 (IL-7) (Figure 2A ). IL-7 levels were also elevated in patients with LNB. Levels of the T-cell growth factor were comparably elevated in patients with headaches or cognitive difficulties and did not differ significantly between patients with Lyme disease who were seropositive (ELISA plus Western blot analysis) and those who had been treated previously for Lyme disease but were seronegative at the time of cytokine analysis. Overall, IL-7 levels were similarly elevated in patients with encephalopathy and headache, with or without a history of Lyme disease ( Figure 2F ). Cranial neuritis 2 (4) CSF from 1 Lyme encephalopathy, 1 non-Lyme encephalopathy, and 3 Lyme headache patients was unavailable for cytokine analysis.
IL-7 is a member of a family of T-cell-regulating cytokines whose receptors share the common γ-chain receptor subunit [26] . In a follow-up experiment, we assayed other γ-chain cytokines not included in the original multiplex, as well as thymic stromal lymphopoietin (TSLP), which shares the IL-7 receptor α subunit with IL-7. Levels of most of the common γ-chain cytokines were undetectable in a majority of individuals; however, interleukin 2 and TSLP correlated with IL-7, and TSLP levels were significantly elevated in patients with encephalopathy and/or headache compared with normal controls; patients without Lyme disease had higher levels than those with Lyme disease (Figure 2E and 2F) .
Serum Th17 Type Response in Encephalopathy
A recent report suggested that a Th17-type immune response, with increased serum interleukin 23 (IL-23) at the time of Lyme disease diagnosis, correlates with development of nonspecific symptoms persisting after usually effective antibiotic treatment (posttreatment Lyme disease symptoms) [13] . We found that IL-23 was undetectable in serum from about 75% of patients in our study (compared with about 50% reported by Strle et al [13] ) and its levels were not significantly elevated in patient groups compared with normal controls (Supplementary  Table S3 ). However, we did detect significant elevations in the A, CSF CXCL13 levels in patients with a range of neuroinflammatory (NI) and nonneuroinflammatory disorders (NNIDs). Boxes represent 25th-75th percentiles; line, median; whiskers, range (minimum to maximum); dotted horizontal lines, highest and lowest detectable standards; dashed horizontal line at 250 pg/mL, proposed diagnostic cutoff for LNB [24] . Parenthetical numbers denote the number of patients per group. CSF CXCL13 levels were significantly higher (P < major Th17-produced cytokines, interleukin 17A and 17F, in both patients with and patients without Lyme disease who had neurobehavioral symptoms ( Figure 2B , 2C, and 2F). Correlated with interleukin 17F, the chemokine macrophage inflammatory protein 1α/CCL3 also had significantly elevated levels in these patients compared with normal controls (Figure 2D and 2F) .
PC analysis of the serum data set revealed that the correlated analytes contributing to the first PC (PC1), responsible for about 50% of the variability, included both Th17-and Th1-related cytokines, as well as growth factors granulocyte-macrophage colony-stimulating factor and interleukin 9 ( Figure 3 ). Although detectable in only a subset of samples, IL-23 was a strong contributor to this PC. Th17-related cytokines were significant contributors to PC1-3, whereas the T-cell-regulating factors IL-7, interleukin 2, and TSLP also influenced PC3. Scores for each of these components were significantly elevated in patients with headache and/or encephalopathy compared with normal controls ( Figure 3B-3D) ; as with the individual cytokines, these were comparable in patients with or without Lyme disease. None of the cytokines analyzed in this study had elevated CSF levels in patients with headache or encephalopathy, compared with controls undergoing myelography (data not shown).
DISCUSSION
Misattribution of nonspecific symptoms to Lyme disease in general, and neuroborreliosis in particular, has contributed substantially to widespread concerns about "chronic Lyme disease, " a poorly defined, nonantibiotic responsive [27] symptom complex. To explore possible mechanisms in neuroborreliosis and Lyme encephalopathy we assessed immune mediators in patients with or without LNB, with Lyme encephalopathy, and with symptomatically similar syndromes, including assessing markers recently reported to be associated with posttreatment persisting neurobehavioral symptoms, also known as posttreatment Lyme disease symptoms. In our study, a majority of patients (82%) referred with encephalopathy and/or headache and a clinical history of Lyme disease had been treated previously for Borrelia infection. Of these, 44% experienced continuing or new neurobehavioral symptoms ≥6 months after antibiotic treatment and could be considered to have posttreatment Lyme disease symptoms according to proposed definitions [28, 29] .
Although it is unclear whether there is a causal relationship between antecedent Lyme disease and posttreatment Lyme disease symptoms, especially when new symptoms develop long after treatment, concern remains among patients and physicians . The number of patients per group is shown in parentheses below the x-axis labels. Open symbols represent seronegative patients with no history of Lyme disease; bars, median values; dotted lines, lowest detectable standard. Multiplicityadjusted P values were determined using Dunn multiple-comparison posttests. F, Cytokine values did not differ between patients with encephalopathy and those with headache; data from these patients (combined) are replotted by Lyme disease history. Cytokine values from patients with a history of Lyme disease (solid gray boxes; n = 85-88) were compared with values from those without a history of Lyme disease (hatched boxes; n = 15) and from normal controls (NC; white boxes; n = 50). Boxes represent 25th-75th percentiles; lines, medians; whiskers, range (minimum to maximum). The median serum levels of all analyzed cytokines are shown in Supplementary Table S3. *P < .05; ** †P < .01; **** ‡P < .001. Abbreviations: LNB, Lyme neuroborreliosis; NS, not significantly different.
that such symptoms indicate that spirochetes have eluded treatment and invaded the CNS. We measured the levels of markers previously associated with neuroborreliosis in a wide range of patients with neurologic and neurobehavioral symptoms to determine whether any could aid in discriminating active CNS Borrelia infection from other neurologic infections or neuroinflammatory disorders, as well as nonneuroinflammatory causes of such symptoms.
Several retrospective [4, 16, 17, 19, 21, 23, 24] and prospective [18, 20, 22, 25] European studies suggest that CSF CXCL13 might have sufficient sensitivity and specificity to be a useful diagnostic marker of LNB. Extreme elevations in CSF CXCL13 in definite LNB in our study are consistent with the European results and suggest that the strain of Borrelia responsible for Lyme disease in North America elicits a similar response.
At a previously proposed diagnostic cutoff of 250 pg/mL [24] , we found CSF CXCL13 to be 75% sensitive (95% confidence interval, 35%-97%) for detecting definite LNB, with 85% specificity (66%-96%) versus non-Lyme disease patients with a range of conditions associated with CSF pleocytosis. Specificity versus nonneuroinflammatory disorders was 99% (95% confidence interval, 95%-100%). The 1 patient with Lyme encephalopathy with a CSF CXCL13 level exceeding this cutoff was previously untreated, strongly seropositive, had had a tick bite and erythema migrans 16 months earlier, and had neuropathy and arthralgias. CSF was acellular with a normal protein level, including IgG concentration. The CSF antibody index was borderline elevated at 0.89, although serum and CSF ODs were so highly elevated that the ratio is probably uninterpretable. It is unknowable whether this patient had recovered spontaneously from LNB, with residual elevated antibody index and CXCL13, or whether there was another explanation.
CSF CXCL13 has been shown to be produced early in LNB, but few studies have addressed whether measuring this chemokine can effectively discriminate between early neuroborreliosis and other inflammatory conditions associated with CSF pleocytosis. The presence of the chemokine in CSF is not unique to LNB-it is also elevated in patients with neurosyphilis [30, 31] , HIV [8, 24] , CNS lymphoma [32] , and various autoimmune conditions, including multiple sclerosis [33] . The overlapping concentrations of CSF CXCL13 we observed in seropositive patients strongly suspected of having early LNB, and seronegative patients with other causes of neuroinflammation, suggest that the chemokine may lack adequate sensitivity and specificity to identify LNB in patients without detectable ITAb. Because it remains possible that these patients did not actually have CNS B. burgdorferi infection, larger, prospective longitudinal studies are needed to further address this question.
Our data demonstrate no evidence of CNS infection or neuroinflammation in patients with Lyme disease with encephalopathy and/or headaches. These patients, with clinically documented Lyme disease (present or past) but normal CSF clinical test results, do not have significant elevations in CSF cytokines and chemokines that are elevated in LNB and other neuroinflammatory conditions. In the absence of CNS infection or inflammation, altered nervous system function might be caused by systemically produced proinflammatory mediators that cross the blood-brain barrier and are associated with neurobehavioral symptoms, sometimes referred to as sickness behavior [34] in numerous other infections and inflammatory states. Often including fatigue, headaches, and impaired memory and cognition, such symptoms are probably not disproportionately common in Lyme disease [35] .
Strle and colleagues [13] previously reported that elevated serum IL-23 was associated with the development of posttreatment Lyme disease symptoms and correlated with the production of antibodies to the endothelial cell growth factor autoantigen. Although a more recent report failed to find an association between endothelial cell growth factor autoantibodies and posttreatment Lyme disease symptoms [36] , the linking of a heightened Th17-type response to immune dysregulation and persistent symptoms remains intriguing. Th17 cells play an important role in controlling extracellular bacteria but are also implicated in the pathogenesis of a wide range of abnormal inflammatory and autoimmune diseases [37] .
IL-23 was undetectable in serum from the majority of patients analyzed in our study. However, median levels of major Th17-produced cytokines, interleukin 17A and 17F, were significantly higher in serum from patients with encephalopathy and headache than in normal controls. Interestingly, these serum levels did not differ between symptomatic patients with and those without a history of Lyme disease. PC analysis suggests parallel induction of both Th17 and Th1 cell types in Lyme disease and other unrelated illnesses, which may be associated with a range of nonspecific symptoms accompanying the underlying condition. Such symptoms may take time to improve as inflammation resolves gradually after treatment.
A striking finding in our study was the highly significant elevation in serum IL-7 levels in patients with active LNB, as well as in patients with nonspecific neurobehavioral symptoms. This was equally true in patients with and those without Lyme disease , with median levels in the symptomatic groups approximately equal to maximal levels in normal controls. Elevated serum IL-7 has been previously reported in children with both LNB-related and non-Lyme (idiopathic) peripheral facial nerve palsy [38] . IL-7 is an essential growth factor that regulates T-cell homeostasis, and differential expression of IL-7 receptors by different T-cell subsets governs their proliferative responses when circulating IL-7 levels are increased (reviewed in [39, 40] ). Thus, elevated IL-7 can potentially result in T-cell dysregulation and lead to abnormal inflammation. Further characterization of the inflammatory processes apparently associated with nonspecific neurobehavioral symptoms could suggest novel mechanistic insights and potential therapies for patients with this symptom complex-with or without antecedent Lyme disease.
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